UY25904A1 - Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina - Google Patents
Sulfonamidas heterocíclicas inhibidoras de receptores de endotelinaInfo
- Publication number
- UY25904A1 UY25904A1 UY25904A UY25904A UY25904A1 UY 25904 A1 UY25904 A1 UY 25904A1 UY 25904 A UY25904 A UY 25904A UY 25904 A UY25904 A UY 25904A UY 25904 A1 UY25904 A1 UY 25904A1
- Authority
- UY
- Uruguay
- Prior art keywords
- pyridin
- methoxy
- methyl
- pyrimidin
- phenoxy
- Prior art date
Links
- 102000010180 Endothelin receptor Human genes 0.000 title abstract 2
- 108050001739 Endothelin receptor Proteins 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- PWSQPYYJRFUQNY-UHFFFAOYSA-N 4-[4-methoxy-5-(2-methoxyphenoxy)-6-[(5-methylpyridin-2-yl)sulfonylamino]pyrimidin-2-yl]pyridine-2-carboxylic acid Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(N=CC=2)C(O)=O)OC)=C1NS(=O)(=O)C1=CC=C(C)C=N1 PWSQPYYJRFUQNY-UHFFFAOYSA-N 0.000 abstract 1
- 206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000001589 carboacyl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004181 carboxyalkyl group Chemical group 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000008694 endothelial dysfunction Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- -1 hydroxy-lower-alkyl Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- JBMOXASJKXMRQK-UHFFFAOYSA-N methyl 4-[4-methoxy-5-(2-methoxyphenoxy)-6-[(5-methylpyridin-2-yl)sulfonylamino]pyrimidin-2-yl]pyridine-2-carboxylate Chemical compound C1=NC(C(=O)OC)=CC(C=2N=C(OC)C(OC=3C(=CC=CC=3)OC)=C(NS(=O)(=O)C=3N=CC(C)=CC=3)N=2)=C1 JBMOXASJKXMRQK-UHFFFAOYSA-N 0.000 abstract 1
- HWDVVFJLGKKDDY-UHFFFAOYSA-N n-[2-[2-(hydroxymethyl)pyridin-4-yl]-6-methoxy-5-(2-methoxyphenoxy)pyrimidin-4-yl]-5-methylpyridine-2-sulfonamide Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2C=C(CO)N=CC=2)OC)=C1NS(=O)(=O)C1=CC=C(C)C=N1 HWDVVFJLGKKDDY-UHFFFAOYSA-N 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002769 thiazolinyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 230000006442 vascular tone Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Compuestos de fórmula (I), sus sales estables y ésteres derivados farmacéuticamente aceptables, así como procedimientos para su preparación, donde: R1 es piridilo, pirrolilo, imidazolilo, tiazolilo, tiazolinilo u oxazolilo, sustiuidos opcionalmente con halógeno, alquilo inferior, hidroxi-alquilo-inferior o alquenilo inferior; R2 es R21 ( siendo R1: ciano, hidroxi-alquilo-inferior, carboxi, entre otros) , -O-R22-, -N-R22 ( siendo R22: hidrógeno, alcanoilo inferior, carboxialquilo inferior, alcoxicarbonilo inferior, entre otros) o heterociclilo, el cual puede estar opcionalmente mono-, di- o tri-sustituido independientemente; X es -CH- o -N-. Ejemplos de compuesto seleccionados de fórmula (I): Ácido 4-[4-metoxi-5-(2-metoxi-fenoxi)-6-(5-metil-piridin-2-sulfonilamino)-pirimidin-2-il]-piridin-2-carboxílico; Éster metílico del ácido 4-[4-metoxi-5-(2-metoxi-fenoxi)-6-(5-metil-piridin-2-sulfonilamino)-pirimidin-2-il]-piridin-2-carboxílico; Ácido 5-metil-piridin-2-sulfónico [2-(2-hidroximetil-piridin-4-il)-6-metoxi-5-(2-metoxi-fenoxi)-pirimidin-4-il]-amida; entre otros. Estos compuestos son inhibidores de receptores de endotelina y pueden por lo tanto, usarse para el tratamiento de trastornos que están asociados con el tono vascular anormal y la disfunción endotelial. VER REIVINDICACIONES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99100784 | 1999-01-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25904A1 true UY25904A1 (es) | 2001-07-31 |
Family
ID=8237359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25904A UY25904A1 (es) | 1999-01-18 | 2000-01-14 | Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6242601B1 (es) |
| EP (1) | EP1149091B1 (es) |
| JP (1) | JP3983477B2 (es) |
| KR (1) | KR100478797B1 (es) |
| CN (1) | CN1340049A (es) |
| AR (1) | AR029879A1 (es) |
| AT (1) | ATE389648T1 (es) |
| AU (1) | AU763112B2 (es) |
| BR (1) | BR0007595A (es) |
| CA (1) | CA2359363C (es) |
| CO (1) | CO5150187A1 (es) |
| CZ (1) | CZ20012546A3 (es) |
| DE (1) | DE60038365D1 (es) |
| ES (1) | ES2301476T3 (es) |
| GC (1) | GC0000248A (es) |
| HR (1) | HRP20010515A2 (es) |
| HU (1) | HUP0200021A3 (es) |
| IL (2) | IL144055A0 (es) |
| MA (1) | MA27124A1 (es) |
| MY (1) | MY121136A (es) |
| NO (1) | NO322800B1 (es) |
| NZ (1) | NZ512662A (es) |
| PE (1) | PE20001421A1 (es) |
| PL (1) | PL350093A1 (es) |
| RU (1) | RU2224757C2 (es) |
| TR (1) | TR200102071T2 (es) |
| TW (1) | TWI284642B (es) |
| UY (1) | UY25904A1 (es) |
| WO (1) | WO2000042035A1 (es) |
| YU (1) | YU50001A (es) |
| ZA (1) | ZA200105279B (es) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US20080300281A1 (en) * | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| US7517880B2 (en) * | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US20080269265A1 (en) * | 1998-12-22 | 2008-10-30 | Scott Miller | Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| ME00275B (me) * | 1999-01-13 | 2011-02-10 | Bayer Corp | ω-KARBOKSIARIL SUPSTITUISANI DIFENIL KARBAMIDI KAO INHIBITORI RAF KINAZE |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US6417360B1 (en) * | 1999-03-03 | 2002-07-09 | Hoffmann-La Roche Inc. | Heterocyclic sulfonamides |
| MY140724A (en) | 2000-07-21 | 2010-01-15 | Actelion Pharmaceuticals Ltd | Novel arylethene-sulfonamides |
| ES2260318T3 (es) * | 2000-12-18 | 2006-11-01 | Actelion Pharmaceuticals Ltd. | Nuevas sulfamidas y su utilizacion como antagonistas del receptor de endotelina. |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US7371763B2 (en) * | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US20030232765A1 (en) * | 2001-12-03 | 2003-12-18 | Bayer Corporation | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
| DK1478358T3 (da) | 2002-02-11 | 2013-10-07 | Bayer Healthcare Llc | Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese |
| US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| EP1580188B9 (en) * | 2002-02-11 | 2012-05-23 | Bayer HealthCare, LLC | Aryl ureas as kinase inhibitors |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| CA2507334C (en) * | 2002-12-02 | 2013-05-07 | Actelion Pharmaceuticals Ltd. | Pyrimidine-sulfamides and their use as endothelian receptor antagonist |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| US7269460B2 (en) * | 2003-02-28 | 2007-09-11 | Medtronic, Inc. | Method and apparatus for evaluating and optimizing ventricular synchronization |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| SI1663978T1 (sl) | 2003-07-23 | 2008-02-29 | Bayer Pharmaceuticals Corp | Fluoro substituirana omega-karboksiaril difenil secnina za zdravljenje ali preprecevanje bolezni instanj |
| EP1595880A1 (en) * | 2004-05-13 | 2005-11-16 | Speedel Pharma AG | Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists |
| CR9465A (es) * | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
| US20100022568A1 (en) * | 2006-04-13 | 2010-01-28 | Actelion Pharmaceeuticals Ltd. | Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis |
| US20090263472A1 (en) | 2006-05-29 | 2009-10-22 | Nicox S.A. | Endothelin receptor antagonist derivatives |
| AR062501A1 (es) | 2006-08-29 | 2008-11-12 | Actelion Pharmaceuticals Ltd | Composiciones terapeuticas |
| MX2010001837A (es) | 2007-08-17 | 2010-03-10 | Actelion Pharmaceuticals Ltd | Derivados de 4-pirimidinasulfamida. |
| CN110204525B (zh) * | 2014-11-21 | 2022-01-28 | 大金工业株式会社 | 新型的氟代不饱和环状碳酸酯及其制造方法 |
| CN109260164A (zh) * | 2018-10-07 | 2019-01-25 | 威海贯标信息科技有限公司 | 一种阿伏生坦片剂组合物 |
| CN112898208B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用 |
| CN112778215B (zh) * | 2021-01-29 | 2023-06-20 | 中国医科大学 | 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用 |
| TW202329952A (zh) | 2021-12-17 | 2023-08-01 | 瑞士商愛杜西亞製藥有限公司 | 克拉生坦(clazosentan)二鈉鹽之製備方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837708A (en) | 1994-11-25 | 1998-11-17 | Hoffmann-La Roche Inc. | Sulphonamides |
| WO1996016963A1 (de) * | 1994-11-25 | 1996-06-06 | F. Hoffmann-La Roche Ag | Sulfonamide und deren verwendung als heilmittel |
| CA2162630C (en) * | 1994-11-25 | 2007-05-01 | Volker Breu | Sulfonamides |
| TW313568B (es) * | 1994-12-20 | 1997-08-21 | Hoffmann La Roche | |
| DE69612874T2 (de) * | 1995-12-20 | 2001-10-04 | Yamanouchi Pharmaceutical Co., Ltd. | Arylethensulfonamid-derivate und diese enthaltende medikamente |
-
2000
- 2000-01-07 TW TW089100181A patent/TWI284642B/zh not_active IP Right Cessation
- 2000-01-10 AT AT00904889T patent/ATE389648T1/de not_active IP Right Cessation
- 2000-01-10 AU AU26630/00A patent/AU763112B2/en not_active Ceased
- 2000-01-10 WO PCT/EP2000/000103 patent/WO2000042035A1/en not_active Ceased
- 2000-01-10 IL IL14405500A patent/IL144055A0/xx not_active IP Right Cessation
- 2000-01-10 NZ NZ512662A patent/NZ512662A/en unknown
- 2000-01-10 TR TR2001/02071T patent/TR200102071T2/xx unknown
- 2000-01-10 KR KR10-2001-7008996A patent/KR100478797B1/ko not_active Expired - Fee Related
- 2000-01-10 CA CA002359363A patent/CA2359363C/en not_active Expired - Fee Related
- 2000-01-10 RU RU2001122114/04A patent/RU2224757C2/ru not_active IP Right Cessation
- 2000-01-10 EP EP00904889A patent/EP1149091B1/en not_active Expired - Lifetime
- 2000-01-10 CZ CZ20012546A patent/CZ20012546A3/cs unknown
- 2000-01-10 ES ES00904889T patent/ES2301476T3/es not_active Expired - Lifetime
- 2000-01-10 CN CN00803754A patent/CN1340049A/zh active Pending
- 2000-01-10 PL PL00350093A patent/PL350093A1/xx not_active Application Discontinuation
- 2000-01-10 YU YU50001A patent/YU50001A/sh unknown
- 2000-01-10 HR HR20010515A patent/HRP20010515A2/hr not_active Application Discontinuation
- 2000-01-10 DE DE60038365T patent/DE60038365D1/de not_active Expired - Lifetime
- 2000-01-10 BR BR0007595-7A patent/BR0007595A/pt not_active Application Discontinuation
- 2000-01-10 JP JP2000593603A patent/JP3983477B2/ja not_active Expired - Lifetime
- 2000-01-10 HU HU0200021A patent/HUP0200021A3/hu unknown
- 2000-01-13 PE PE2000000025A patent/PE20001421A1/es not_active Application Discontinuation
- 2000-01-13 US US09/482,810 patent/US6242601B1/en not_active Expired - Fee Related
- 2000-01-14 UY UY25904A patent/UY25904A1/es unknown
- 2000-01-14 CO CO00001821A patent/CO5150187A1/es unknown
- 2000-01-14 AR ARP000100159A patent/AR029879A1/es unknown
- 2000-01-14 MY MYPI20000124A patent/MY121136A/en unknown
- 2000-01-17 GC GCP2000481 patent/GC0000248A/en active
-
2001
- 2001-06-26 ZA ZA200105279A patent/ZA200105279B/en unknown
- 2001-06-28 IL IL144055A patent/IL144055A/en unknown
- 2001-07-12 NO NO20013454A patent/NO322800B1/no unknown
- 2001-07-17 MA MA26270A patent/MA27124A1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25904A1 (es) | Sulfonamidas heterocíclicas inhibidoras de receptores de endotelina | |
| AR059249A1 (es) | Compuesto amina trisustituido | |
| PE20140858A1 (es) | Derivados de piperidina como inhibidores de renina | |
| AR059248A1 (es) | Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| PE20070808A1 (es) | COMPUESTOS DERIVADOS DE ISOQUINOLINA COMO INHIBIDORES DE Rho-QUINASA | |
| AR050953A1 (es) | Compuestos de sulfonamida inhibidores de los receptores de cck1/cck2 duales | |
| PE20091413A1 (es) | (DIHIDRO)PIRROLO[2,1-a] ISOQUINOLINAS | |
| PE20141827A1 (es) | Inhibidores de proteinas quinasas | |
| ES2561425T3 (es) | (Aza)ciclohexanos carbonilados como ligandos de receptor D3 de la dopamina | |
| PE20081454A1 (es) | Derivados de pirazol como moduladores del receptor 5-ht2a de serotonina utiles para el tratamiento de los transtornos relacionados con dicho receptor | |
| PE20070407A1 (es) | Compuestos derivados de pirazina como antagonistas del receptor a2b de adenosina | |
| PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado | |
| AR047538A1 (es) | Piridazinonas como antagonistas de las integrinas alfa4 | |
| ES2567311T3 (es) | 6-(3-Aza-biciclo[3.1.0]hex-3-il)-2-fenil-pirimidinas como antagonistas del receptor de ADP | |
| PE20181144A1 (es) | Derivados de heteroarilo como inhibidores de parp | |
| AR071323A1 (es) | Derivados heterociclicos de piridazinonas activadores de glucoquinasas, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de la diabetes mellitus tipo ii. | |
| PE20091732A1 (es) | Dihidropirazolonas sustituidas y su uso | |
| PE20130184A1 (es) | Compuesto heterociclico | |
| PE20040526A1 (es) | Amidas de 4-alquenil piperidina de indol, azaindol y relacionadas con heterociclicos | |
| TNSN07348A1 (en) | Thiadiazole substituted coumarin derivatives and their use as leukotriene biosynthesis inhibitor | |
| PE20070093A1 (es) | Derivados dihidrobenzofuranos como moduladores del receptor 5-ht2c | |
| AR065850A1 (es) | Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph | |
| NO20080392L (no) | Pyrazolpyridinderivater som inhibitorer av beta-adrenergisk receptorkinase 1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20081222 |